CHARLESTOWN, MA — November 3, 2025 — Leads & Copy —
Solid Biosciences Inc. (Nasdaq: SLDB) reported financial results for Q3 2025 and announced positive interim data from the Phase 1/2 INSPIRE DUCHENNE clinical trial. As of Oct. 31, 2025, 23 participants have been dosed in the INSPIRE DUCHENNE trial. Solid expects to have dosed 30 participants by early 2026, then plans to meet with the FDA in H1 2026 to discuss potential registrational pathways.
SGT-003 has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen. Day 90 biopsy data from 10 treated participants (ages 5-10) showed all participants responded to treatment with mean microdystrophin expression of 58% by western blot and 58% by mass spectrometry.
Solid has activated the first clinical trial site and is screening participants for IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled ex-U.S. clinical trial of SGT-003. Solid has also activated the first clinical trial site and is screening participants for FALCON, a Phase 1b clinical trial evaluating SGT-212 for the treatment of Friedreich’s ataxia. Clinical trial site activation for ARTEMIS, a Phase 1b clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, is expected in Q4 2025.
The company ended Q3 2025 with $236.1 million in cash, cash equivalents and available-for-sale securities. Solid anticipates its cash runway into H1 2027.
Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences
